kidney transplantation
Conditions
Brief summary
- death by infectious disease - infectious burden defined as the number of infections requiring hospitalization and/or proven viral infections including cytomegalovirus and BK-virus replication within a follow-up of 3 years.
Detailed description
- quality of life - biopsy-proven rejection from time of randomization to end of follow-up at 3 years post-transplantation. - Assessment of de novo alloantibody formation as detected by a Luminex-based assay (6 months, 1,2 and 3 years after transplantation) - Assessment of the circulating alloreactive T cells in time (before, 1, 2 and 3 years after transplantation) - Graft function measured by eGFR and 24-hr urine collection - Patient and graft survival
Interventions
DRUGPREDNISONE
DRUGMYCOPHENOLATE MOFETIL
DRUGTACROLIMUS
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - death by infectious disease - infectious burden defined as the number of infections requiring hospitalization and/or proven viral infections including cytomegalovirus and BK-virus replication within a follow-up of 3 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| - quality of life - biopsy-proven rejection from time of randomization to end of follow-up at 3 years post-transplantation. - Assessment of de novo alloantibody formation as detected by a Luminex-based assay (6 months, 1,2 and 3 years after transplantation) - Assessment of the circulating alloreactive T cells in time (before, 1, 2 and 3 years after transplantation) - Graft function measured by eGFR and 24-hr urine collection - Patient and graft survival | — |
Countries
Netherlands
Outcome results
None listed